Deutsches Herzzentrum Berlin
Berlin, State of Berlin, Germany
NCT Number: NCT01227785
This study has 2 purposes:
The first purpose of the study is to test a new family of Boston Scientific Implantable Cardioverter Defibrillators ("ICDs") and cardiac resynchronization therapy ICDs ("CRT-Ds") and show how well these new devices work in patients. This new family is called the INCEPTA ICD and the INCEPTA CRT-D.
The second purpose of the study is to collect data from a feature that monitors breathing. It is called the Respiratory Rate Trend (RRT). These data will help to better understand how changes in breathing relate to changes in clinical conditions.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Berlin, State of Berlin, Germany
Study Purpose
Study purpose I:
To evaluate and document appropriate clinical performance of the INCEPTA (DR and VR) implantable cardioverter defibrillator (ICD) system and the INCEPTA cardiac resynchronization therapy ICD (CRT-D) system and associated application software.
Study purpose II:
Demonstrate the clinical relevance of chronic ambulatory daily median Respiratory Rate Trend (RRT) in HF patients
Study Device
Indication ICD / CRT-D Indication according to standard clinical practice
Study Objectives
The study has two primary objectives, linked to the respective study purposes:
For purpose I:
The objective is to collect data on the clinical performance of the INCEPTA ICD and CRT-D devices during standard clinical use at implant, pre-discharge and at a 1-month post-implant. Clinical performance included analysis of pacing thresholds, pacing impedance, sensing thresholds, number of successfully converted VT/VF episodes, induced episodes detection times, spontaneous episodes, wanded telemetry, adverse events (AEs) and product experiences.
For purpose II:
The objective is to show that daily median respiratory rate increases more in patients who experience an HF-event (Group 1) than in patients who do not experience an HF-event (Group 2).
This is a prospective, multi-centre, field following study.
Up to 35 study centers in the International geography will enrol 120 patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-As soon as 20 ICD patients are included in the study for purpose I, only NYHA Class III patients will be allowed in the study.
Exclusion criteria
Time frame: implant
Left Ventricular (LV) Sensed Amplitude results were reported at implant for CRT-D patients.
Time frame: pre-discharge
Left Ventricular (LV) Sensed Amplitude results were reported pre-discharge for CRT-D patients.
Time frame: 1-month
LV Sensed Amplitude results were reported at 1-month post-implant for CRT-D patients.
Time frame: implant
RA Sensed Amplitude results were reported for implant for CRT-D and ICD patients
Time frame: pre-discharge
RA Sensed Amplitude results were reported at pre-discharge for CRT-D and ICD patients
Time frame: 1-month
RA Sensed Amplitude results were reported at 1-month post-implant for CRT-D and ICD patients
Time frame: implant
RV Sensed Amplitude results were reported at implant for CRT-D and ICD patients
Time frame: pre-discharge
RV Sensed Amplitude results were reported at pre-discharge for CRT-D and ICD patients
Time frame: 1month
RV Sensed Amplitude results were reported at 1-month post-implant for CRT-D and ICD patients
Time frame: implant
LV pacing threshold results were reported for CRT-D patients at implant.
Time frame: pre-discharge
LV pacing threshold results were reported at pre-discharge for CRT-D patients.
Time frame: 1-month
LV pacing threshold results were reported at 1-month post-implant for CRT-D patients.
Time frame: implant
RV pacing threshold results were reported at implant
Time frame: pre-discharge
RV pacing threshold results were reported at pre-discharge
Time frame: 1-month
RV pacing threshold results were reported at 1-month post-implant
Time frame: implant
RA pacing threshold results were reported for implant
Time frame: pre-discharge
RA pacing threshold results were reported at pre-discharge
Time frame: 1-month
RA pacing threshold results were reported at 1-month post-implant
Time frame: implant
LV pacing impedance results at implant were measured in CRT-D.
Time frame: pre-discharge
LV pacing impedance results were reported for pre-discharge visit
Time frame: 1-month
LV pacing impedance results were reported at 1-month post-implant
Time frame: implant
RV pacing impedance results were reported at implant
Time frame: pre-discharge
RV pacing impedance results were reported for pre-discharge
Time frame: 1-month
RV pacing impedance results were reported at 1-month post-implant
Time frame: implant
RA pacing impedance results were reported at implant
Time frame: pre-discharge
RA pacing impedance results were reported at pre-discharge
Time frame: 1-month
RA pacing impedance results were reported at 1-month post-implant
Time frame: Overall study results
Product experiences reported may include the shock impedance noise display, problems encountered with the universal serial bus (USB), a program parameter mismatch, reverse mode switches, electrogram (EGM) noise without oversensing, lead connection issues, or customer device feedback.
Time frame: implant
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
Time frame: 1-month
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
Time frame: 3-month
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
Time frame: implant
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
Time frame: 1-month
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
Time frame: 3-month
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
Time frame: 3-month
Of the total patients that experienced a spontaneous episode, the % of patients with a spontaneous rhythm conversion that was successful was determined.
Time frame: Pre-Discharge visit occurred after implant but prior to 1 month follow-up visit
The Investigators completed a questionnaire based on the performance of the wanded telemetry during device interrogations at pre-discharge follow-up. The number of problems reported were counted from the entire study cohort.
Time frame: Results were captured from implant time window to the first event for patients with HFE, up to an average of 9 months
A comparison of the change in respiratory rate trend over time was made between patients who experienced a protocol-defined HF event (HFE) (Group1: Patients with a HFE) and patients who did not experience a protocol-defined heart failure event (Group 2: Patients without a HFE). Only patients with at least 3 valid daily respiratory rate values (60%) out of each 5-day window were evaluated. The objective was to show that daily median respiratory rate increases more in patients who experience a HFE (Group 1) than in patients who do not experience an HFE (Group 2). A comparison between patients who experience a HFE (Group 1) and patients who do not experience a HFE (Group 2). Two average daily median respiratory rates were done per patient: 60 to 56 days before an index time and 11 to 7 days before the same index time; the difference between these two averaged daily median respiratory rates was done. Index time=day of the first HFE (Group 1) and day of 6-month visit (Group 2).
Guidant Corporation
Industry
Next Generation INCEPTA ICD and CRT-D Field Following Study: Respiratory Rate Trend Evaluation in Heart Failure (HF) Patients
Acronym: NOTICE-HF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05237323
Cardiomegaly, Cardiomyopathies
Moscow, Bol'shaya Pirogovskaya Street 6, 1 Building ,, Russia
View Trial DetailsNCT03016754
Cardiovascular Diseases, Death
Birmingham, Alabama, United States
View Trial DetailsNCT04675957
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Graz, Austria
View Trial DetailsNCT03185832
Arrhythmias, Cardiac, Cardiovascular Diseases
Ichinomiya, Aichi-ken, Japan
View Trial Details